Ishita Drugs and Industries Limited

ISHITADR6

INE806D01016

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:57 28/06/2024 pm IST			5-day change	1st Jan Change
66.76 ^INR	+1.54%		+1.83%	-7.20%

30/05	Ishita Drugs and Industries Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI
13/02	Ishita Drugs and Industries Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI

Ishita Drugs & Industries Limited Reports Earnings Results for the First Quarter Ended June 30, 2020

August 13, 2020 at 05:56 pm IST

Ishita Drugs & Industries Limited announced earnings results for the first quarter ended June 30, 2020. For the first quarter, the company announced sales was INR 23.040 million compared to INR 38.606 million a year ago. Net income was INR 906,000 compared to INR 1.220 million a year ago. Basic earnings per share was INR 0.3 compared to INR 0.41 a year ago.

Latest news about Ishita Drugs and Industries Limited

Ishita Drugs and Industries Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	30/05	CI
Ishita Drugs and Industries Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	13/02	CI
Ishita Drugs and Industries Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	08/11	CI
Ishita Drugs and Industries Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	12/23/12	CI
Ishita Drugs and Industries Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	30/23/30	CI
Ishita Drugs and Industries Limited Reports Earnings Results for the Nine Months Ended December 31, 2022	14/23/14	CI
Ishita Drugs and Industries Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	14/22/14	CI
Ishita Drugs and Industries Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	13/22/13	CI
Ishita Drugs and Industries Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	14/22/14	CI
Ishita Drugs and Industries Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	02/21/02	CI
Ishita Drugs and Industries Limited Reports Earnings Results for the First quarter Ended June 30, 2021	13/21/13	CI
Ishita Drugs and Industries Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	30/21/30	CI
Ishita Drugs and Industries Limited Announces Appointment of Srushti Pandya as Company Secretary and Compliance Officer, Effective February 4, 2021	04/21/04	CI
Ishita Drugs and Industries Limited Announces Resignation of Vijay Shah from the Post of Company Secretary and Compliance Officer	04/21/04	CI
Ishita Drugs and Industries Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020	04/21/04	CI
Ishita Drugs and Industries Limited Reports Earnings Results for the Second Quarter Ended September 30, 2020	09/20/09	CI
Ishita Drugs & Industries Limited Appoints Vijay Shah as Company Secretary and Compliance Officer	31/20/31	CI
Ishita Drugs & Industries Limited Reports Earnings Results for the First Quarter Ended June 30, 2020	13/20/13	CI
Ishita Drugs & Industries Limited Accepts Resignation of Prakash Ranjan Rastogi from the Position of Independent Non-Executive Director	30/20/30	CI
Ishita Drugs & Industries Limited Announces Resignation of Niharika Shah as Company Secretary and Compliance Officer	30/20/30	CI
Ishita Drugs & Industries Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2020	30/20/30	CI
Ishita Drugs & Industries Limited Reports Earnings Results for the Third Quarter Ended December 31, 2019	11/20/11	CI
Ishita Drugs & Industries Limited Reports Earnings Results for the Second Quarter Ended September 30, 2019	12/19/12	CI
Ishita Drugs & Industries Limited Approves Resignation of Shyamkumar Agrawal from the Position of Independent Director	12/19/12	CI
Ishita Drugs and Industries Ltd. Reports Earnings Results for the First Quarter Ended June 30, 2019	13/19/13	CI

Chart Ishita Drugs and Industries Limited

Duration

Period

Chart Ishita Drugs and Industries Limited

More charts

Company Profile

Ishita Drugs and Industries Limited is a manufacturer of various active pharma ingredients (APIs) (bulk actives and their salts), drug intermediates, excipients, and fine chemicals. The Company's APIs include sulpha drugs/sulfonamides, vitamins, fluoroquinolones, antibiotics, anthelmintics, iodides and citrates (salts), food additive/excipients, and others. Its drug intermediates include 4- Sulfonamido Phenyl Hydrazine Hydrochloride (Celecoxib Intermediate), 4- Chloro Phenyl Hydrazine Hydrochloride (intermediate for Indole Carboxylic Acid), L-Alanine Benzylester Tosylate, 5 Cyano Phthalide (Citalopram Intermediate), Indole 2 Carboxylic Acid, Ethyl 3-Benzoyl Acrylate, Hexa Methyl Disilazane, 5-Chloromethopabate, and others. Its fine chemicals include salicylanilide, para bromo toluene, pyridine hydrobromide, potassium phthalimide, nicotinic acid hydrazide, 3 amino pyridine, methyl iodide. The Company has three manufacturing facilities located in the state of Gujarat.

Sector

Pharmaceuticals

Calendar

12/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ISHITA DRUGS AND INDUSTRIES LIMITED	-7.20%	2.39M
ELI LILLY AND COMPANY	+55.32%	815B
NOVO NORDISK A/S	+44.05%	641B
JOHNSON & JOHNSON	-6.75%	352B
MERCK & CO., INC.	+13.56%	314B
ABBVIE INC.	+10.68%	303B
ASTRAZENECA PLC	+16.57%	242B
NOVARTIS AG	+13.31%	218B
AMGEN INC.	+8.48%	168B
PFIZER, INC.	-2.81%	159B